VesiculoVax - Preclinical-Stage Prophylactic Vaccines for Chikungunya Virus

Program Status:
The vaccine has demonstrated single dose protection against lethal infection in the mouse model of disease. Pre-IND discussions have been held with the FDA and pre-clinical safety studies (i.e repeat dose toxicology, neurovirulence and biodistribution) have been completed. The candidate is scheduled to enter Phase I clinical evaluation in 2021.

Unmet Medical Need:
This mosquito transmitted virus is historically endemic to tropical areas of Africa and Southeast Asia. However, the mosquito vector is now widely distributed in Europe and the Americas, with recent outbreaks having spread to Europe and individuals returning to the United States from endemic areas.